| scholarly article | Q13442814 |
| systematic review | Q1504425 |
| P356 | DOI | 10.1111/AJT.12795 |
| P698 | PubMed publication ID | 25088685 |
| P2093 | author name string | G. R. Russ | |
| J. Eris | |||
| W. H. Lim | |||
| B. Pussell | |||
| D. Witcombe | |||
| J. Kanellis | |||
| Z. Wiid | |||
| P2860 | cites work | The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 |
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials | Q33371189 | ||
| Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial | Q33394235 | ||
| Strategies to improve long-term outcomes after renal transplantation | Q34539775 | ||
| Immunosuppression in renal transplantation: some aspects for the modern era. | Q37227882 | ||
| Chronic renal allograft injury: early detection, accurate diagnosis and management. | Q38035660 | ||
| Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy | Q40025515 | ||
| Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial | Q42171624 | ||
| Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer | Q42503484 | ||
| Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. | Q42620122 | ||
| Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. | Q43067943 | ||
| Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination | Q43224194 | ||
| The natural history of chronic allograft nephropathy | Q44688416 | ||
| Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study | Q45153736 | ||
| Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus. | Q45923643 | ||
| Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. | Q46005391 | ||
| Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial | Q46155747 | ||
| The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients | Q46233987 | ||
| Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients | Q46317021 | ||
| Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study | Q46510645 | ||
| Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation | Q46696150 | ||
| A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. | Q46702756 | ||
| The effect of sirolimus in the development of chronic allograft nephropathy | Q46763344 | ||
| Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients | Q46763752 | ||
| Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function | Q46825310 | ||
| Reduced exposure to calcineurin inhibitors in renal transplantation | Q46840533 | ||
| Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks | Q46856408 | ||
| Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. | Q50654391 | ||
| Sirolimus interferes with iron homeostasis in renal transplant recipients. | Q50718380 | ||
| Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. | Q54579642 | ||
| Sirolimus and secondary skin-cancer prevention in kidney transplantation. | Q55056496 | ||
| Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids | Q56908156 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| immunosuppression | Q1455316 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 2106-19 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients | |
| P478 | volume | 14 |
| Q35805955 | A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology |
| Q92443757 | Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink? |
| Q39330060 | Breast Cancer and Transplantation. |
| Q38747503 | CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials |
| Q38779769 | Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. |
| Q38668601 | Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. |
| Q47309233 | Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial |
| Q59341129 | Cancer and mTOR inhibitors in kidney transplantation recipients |
| Q59360475 | Cancer in kidney transplant recipients |
| Q40540152 | Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation. |
| Q40134753 | Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation |
| Q33912913 | Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience |
| Q64930674 | Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation. |
| Q53425824 | Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. |
| Q54208955 | Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients. |
| Q40483831 | Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis |
| Q36255504 | Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials |
| Q42328635 | Efficacy and safety of early tacrolimus conversion to sirolimus after kidney transplantation: Long-term results of a prospective randomized study |
| Q38786418 | Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation |
| Q40132359 | Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study. |
| Q38391150 | Immunological risks of minimization strategies |
| Q42673169 | Immunosuppressants and new onset gallstone disease in patients having undergone renal transplantation. |
| Q40141033 | Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial |
| Q42175189 | Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells |
| Q39079080 | Lessons learned from the world's first successful penis allotransplantation |
| Q48656799 | Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation |
| Q40373461 | Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation. |
| Q39573385 | Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. |
| Q64260637 | Non-immunological complications following kidney transplantation |
| Q59101873 | Overview of Cellular Transplantation in Diabetes Mellitus: Focus on the Metabolic Outcome |
| Q57151742 | Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation |
| Q41218897 | Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. |
| Q64110911 | Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation |
| Q38914374 | Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. |
| Q55452264 | Successful treatment of recurrent immunoglobulin a nephropathy using steroid pulse therapy plus tonsillectomy 10 years after kidney transplantation: a case presentation. |
| Q53482970 | Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts. |
| Q42517229 | The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients |
| Q93052080 | The Interferon-Gamma +874 A/T Polymorphism Is Not Associated With CMV Infection After Kidney Transplantation |
| Q57489240 | The Risk Factors of mTORi-Associated Posttransplant Proteinuria |
| Q38831291 | Torque Teno Virus Load-Inverse Association With Antibody-Mediated Rejection After Kidney Transplantation. |
| Q38593456 | What immunosuppression should be used for old-to-old recipients? |
| Q36527132 | mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors |
Search more.